
    
      this is a randomized, double-blinded, parallel, active-controlled clinical phase III study.
      the primary objective is to evaluate the efficacy and safety of CMAB807 treatment compared
      with Prolia in Chinese postmenopausal women with osteoporosis at high risk of fracture.

      Subjects should sequentially enrolled according to the protocol in one of two arms. Subjects
      who entered in test arm would receive 60mg of CMAB807 subcutaneously every 6 months for one
      year, while those who entered in control arm should receive 60mg of Prolia subcutaneously
      every 6 months for one year. Meanwhile, every subject should taking 600mg calcium and 400IU
      vitamin D daily from successfully screening to the end of study.
    
  